Trial Profile

A study of Cytomegalovirus-specific T-cell therapy for the treatment of cytomegalovirus infection

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 11 May 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adimlecleucel (Primary)
Indications Cytomegalovirus infections
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Atara Biotherapeutics

Most Recent Events

11 May 2016 New trial record
05 May 2016 According to an Atara Biotherapeutics media release, the company plans to discuss clinical trial design for Cytomegalovirus Cytotoxic T-Lymphocyte (CMV-CTLs) with FDA this year and intends initiate this trial in the year 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com